Group Visits for High Risk Type 1 Diabetes (T1D)

Description

The investigators propose to conduct a pilot prospective cohort study to assess the impact of shared medical appointments (SMA) visits in underserved youth with poorly controlled type 1 diabetes (T1D). The trial will employ an enrollment visit, SMA visits every 3 months over a 12 month study period, followed by a 6-month observational period to assess feasibility and acceptability of SMA and the impact on glycemic control, self-management skills, and health related quality of life.

Conditions

Type 1 Diabetes

Study Overview

Study Details

Study overview

The investigators propose to conduct a pilot prospective cohort study to assess the impact of shared medical appointments (SMA) visits in underserved youth with poorly controlled type 1 diabetes (T1D). The trial will employ an enrollment visit, SMA visits every 3 months over a 12 month study period, followed by a 6-month observational period to assess feasibility and acceptability of SMA and the impact on glycemic control, self-management skills, and health related quality of life.

Group Visits to Improve Technology Use, Glycemic Control, and Quality of Life in High Risk Children With Type 1 Diabetes

Group Visits for High Risk Type 1 Diabetes (T1D)

Condition
Type 1 Diabetes
Intervention / Treatment

-

Contacts and Locations

Washington

Children's National Hospital, Washington, District of Columbia, United States, 20010

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients clinically diagnosed with T1D managed with insulin injections for at least 1 year
  • * Non-Hispanic Black or Latinx ethnicity
  • * Public healthcare insurance
  • * Male or female ages ≥ 8 and \< 12 years
  • * Poorly controlled T1D: one A1c value \> 8% in the preceding year
  • * Fluent in English as the Dexcom technology is currently available only in English
  • * Participation of the primary diabetes caregiver
  • * Use of insulin pump therapy for diabetes management at time of enrollment
  • * Major illnesses other than T1D
  • * Significant cognitive limitations and major psychiatric disorders in the child or
  • * Concurrent use of any non-insulin diabetes medication to control blood glucose levels.
  • * Concurrent participation in any other clinical studies during study period

Ages Eligible for Study

8 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Children's National Research Institute,

Shideh Majidi, MD, PRINCIPAL_INVESTIGATOR, Children's National Research Institute

Study Record Dates

2025-07